+ +

•  

   

     Black line: Control Antigen (100 ng); Purple line: Antigen(10ng); Blue line: Antigen (50 ng); Red line: Antigen (100 ng);    

  
  

•  

   

     Flow cytometric analysis of Hela cells using TCL1A mouse mAb (green) and negative control (red).    

  
  

The TCL1A (T-cell leukemia/lymphoma 1A) antibody is a tool used to detect the TCL1A protein, encoded by the TCL1A gene located on chromosome 14q32.1. Initially identified through its involvement in chromosomal translocations in T-cell prolymphocytic leukemia (T-PLL), TCL1A functions as an oncogene. The protein forms homodimers and interacts with kinases like AKT, enhancing their activity to promote cell survival, proliferation, and inhibition of apoptosis. Normally, TCL1A is expressed in embryonic tissues and restricted populations of immune cells, such as thymocytes and germinal center B-cells. However, its dysregulated overexpression in malignancies—triggered by chromosomal rearrangements, gene amplifications, or epigenetic changes—drives oncogenesis in T-cell leukemias, B-cell lymphomas (e.g., chronic lymphocytic leukemia), and other cancers.

The TCL1A antibody is widely used in research and diagnostics to study protein expression patterns via techniques like immunohistochemistry, Western blotting, and flow cytometry. Its detection aids in distinguishing T-PLL from other leukemias and provides insights into cancer progression mechanisms. Additionally, TCL1A's role in modulating AKT signaling has made it a biomarker for therapeutic targeting, with studies exploring its inhibition to counteract tumor growth. This antibody remains crucial for understanding TCL1A's pathological contributions and developing targeted cancer therapies.